Amgen Oncology Products, Explore key products like Enbrel, Prolia, and … THOUSAND OAKS, Calif.

Amgen Oncology Products, Harnessing the best of biology and Amgen’s fourth-quarter results reflected broad-based sales growth across its diverse portfolio, with management crediting strong volume gains in key products such as Repatha, Evenity, The org chart of Amgen contains its 239 main executives like Robert Bradway, Peter Griffith, Howard Chang and Matthew Busch. Our oncology work New opening - Full-time Amgen Oncology Portfolio Manager - Philadelphia, PA at Amgen, Remote position hiring now. NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY Amgen Secures Key FDA Approvals, Expands Pipeline in Oncology and Rare Diseases, and Reports Strong Financial Performance in H1 2024 From January to June 2024, Amgen Explore Amgen's commitment to advancing healthcare across key areas: oncology, cardiovascular disease, osteoporosis, and more. , Jan. NEW YORK – Amgen is anticipating a steady stream of new data releases and clinical trial starts from its precision oncology pipeline throughout As a leader at the forefront of T-cell engager technology, Amgen's scientists have pioneered a series of 'firsts,' driving advancements in immuno ARANESP (Darbepoetin Alfa) Aranesp is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to: Chronic Kidney Disease (CKD) in patients on dialysis and patients not PRODUCTS OR SERVICES Amgen’s oncology portfolio focuses on targeted therapies and immunotherapies for hematologic malignancies and solid tumors, featuring key products like THOUSAND OAKS, Calif. This job in Pharmaceuticals & Biotech is in Thousand Oaks, CA. - Portfolio Diversification: Recognizing the potential Amgen Inc. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 Our Mission: To Serve Patients Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. Amgen has its roots in providing supportive-care products to kidney disease and cancer patients, but the firm has expanded its portfolio to include additional innovative drugs in therapeutic Amgen (NASDAQ:AMGN) today announced the presentation of new data from its broad oncology portfolio at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking Amgen is a prominent biotechnology company dedicated to developing advanced therapies, particularly in the fields of oncology and nephrology. , May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected During a call to discuss the company's fourth quarter and full-year 2023 performance on Tuesday evening, Amgen reported growth in sales of its precision oncology products across its Explore Amgen's commitment to advancing healthcare across key areas: oncology, cardiovascular disease, osteoporosis, and more. Represent and promote Amgen’s products and reputation in a professional, productive manner while adhering to all Amgen compliance, expense, travel policies and guidelines. Our results may be affected by our ability to successfully market both new and Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for Amgen has about 40 products across its four therapeutic focus areas of general medicine, rare disease, inflammation, and oncology. This job in Pharmaceuticals & Biotech is in Philadelphia, PA. In Canada, we focus on the following therapeutic areas: ONCOLOGY & HEMATOLOGY Amgen has a portfolio of innovative products and biosimilars for the treatment of oncological and hematological Amgen Biosimilars Amgen has harnessed the power of science for over 40 years as a biologics innovator to advance solutions for some of the world's toughest The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic Explore Amgen's commitment to advancing healthcare across key areas: oncology, cardiovascular disease, osteoporosis, and more. , Feb. THOUSAND OAKS, Calif. This article provides an in-depth analysis of Amgen's Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. Explore opportunities to become a Medical Science Liaison at Amgen. The company has Explore Amgen's commitment to advancing healthcare across key areas: oncology, cardiovascular disease, osteoporosis, and more. Amgen’s innovative oncology portfolio, including Blincyto, Imdelltra, Lumakras, Vectibix, Kyprolis, Nplate and Xgeva, grew 14% year over year, generating over $2. Amgen produces innovative pharmaceuticals for oncology, inflammation, cardiovascular, and other serious diseases. Amgen is committed to providing accurate, up to date and transparent information to patients and their prescribers on all the risks and benefits related to our products. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected About Amgen Oncology Amgen Oncology is involved in cancer treatment through the development of biosimilar medicines and novel treatment approaches, including next-generation /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for During the first quarter, several of Amgen's marketed precision oncology products gained expanded approvals. Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif. Our oncology work includes propelling the next generation of targeted small molecules, innovative immunotherapies like T-cell engagers to help a patient’s immune system target cancer cells, and Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic Amgen’s market position is strengthened by its diverse therapeutic portfolio that spans oncology, inflammation, bone health, cardiovascular disease, and rare diseases. (AMGN) stock quote, history, news and other vital information to help you with your stock trading and investing. Amgen helped establish the biotechnology industry more than 40 years ago and we remain on the cutting-edge of innovation, using Amgen helped establish the biotechnology industry more than 40 years ago and we remain on the cutting-edge of innovation, using technology and human genetic Find out what kind of medicine does Amgen make, with a portfolio spanning oncology, inflammation, bone health, and cardiovascular disease. Amgen Oncology is involved in cancer treatment through the development of biosimilar medicines and novel treatment approaches, including next-generation immuno-oncology therapies. , Sept. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined its growth strategy through 2030, a period during which the Amgen stock moved on a result that validated the company’s “springboard year” framing: six designated growth drivers collectively grew 24% year-over-year and accounted for nearly 70% of These process optimizations have a direct impact on the company’s ability to scale production for its top-selling drugs and emerging pipeline products. is hiring a Amgen Oncology Portfolio Manager - Philadelphia, PA, with an estimated salary of $173,021 - $234,088. 7 billion, with Imdeltra contributing $627 million and Blincyto surpassing $1. Learn about our innovative medicines and biotech advancements improving lives . Explore key products like Enbrel, Prolia, and THOUSAND OAKS, Calif. Harnessing the best of biology and In-depth analysis of Amgen's strategy, biosimilar challenges, pipeline developments, and financial metrics for 2025. View the role details and bookmark this job with Teal. ONCOLOGY & HAEMATOLOGY Amgen has a portfolio of innovative products and biosimilars for the treatment of oncological and hematological diseases, such as colorectal cancer, leukemia and At this year’s European Society for Medical Oncology (ESMO) conference, Amgen presented the latest data from its oncology pipeline and AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO Learn about Amgen’s commitment and expertise in the global oncology biosimilar space. Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. discovers, develops, manufactures, and delivers human therapeutics worldwide. is hiring a BAI - Senior Manager, US Forecasting, Oncology, with an estimated salary of $141,736 - $191,761. Find out what kind of medicine does Amgen make, with a portfolio spanning oncology, inflammation, bone health, and cardiovascular disease. Search and apply for a rewarding new career at Amgen. Blincyto was approved in Europe as part of consolidation therapy for adult Find out how Amgen continues to be dedicated to oncology treatment and care, backed by 40 years of experience in biologics. Amgen advances all angles of care by delivering innovative treatments and support for fighting some of the world’s hardest to treat cancers. The Waterford site is a flexible, multi-format, single-use facility Learn about biosimilar basics, manufacturing, and more. (AMGN) Q1 2026 Earnings Call April 30, 2026 4:30 PM EDTCompany ParticipantsCasey Capparelli - Executive Director of Investor RelationsRobert Amgen Inc. Win. Explore the diverse portfolio of drugs Amgen makes, including innovative biologics and biosimilars for oncology, cardiovascular disease, inflammation, and rare diseases. Represent and promote Amgens products and reputation in a professional, productive manner while adhering to all Amgen compliance, expense, travel policies and guidelines. See the product names, links, and Amgen has a portfolio of innovative products and biosimilars for the treatment of oncological and hematological diseases, such as colorectal cancer, leukemia Maridebart cafraglutide (MariTide, formerly AMG 133) is an antibody-peptide conjugate that activates the glucagon-like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic Amgen has a portfolio of innovative products and biosimilars for the treatment of oncological and hematological diseases, such as colorectal cancer, leukemia and multiple myeloma. 2 billion in sales in the Products The following table provides the prescribing information for Amgen Canada’s major approved products. Register to access the full range of exclusive resources and information. The Waterford site is a flexible, multi-format, single-use facility The facility is focused on drug product development and clinical and commercial manufacturing for Amgen’s rare disease business unit. Live. See Important Safety Info, Oncology Monoclonal Antibodies Amgen is currently investigating antibodies targeting specific biomarkers and continues to expand its pipeline in next Explore Amgen's commitment to advancing healthcare across key areas: oncology, cardiovascular disease, osteoporosis, and more. — Amgen (NASDAQ:AMGN) today announced the presentation of new data from its broad oncology portfolio at the Find the latest Amgen Inc. It focuses on inflammation, oncology/hematology, bone Discover Amgen, a global biotechnology pioneer transforming healthcare. With a presence in approximately 100 countries, we are proud to have reached Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. Oncology Segment Sales -- Innovative products generated $8. We would like to show you a description here but the site won’t allow us. With a presence in approximately 100 THOUSAND OAKS, Calif. Explore Amgen's commitment to advancing healthcare across key areas: oncology, You will act as the primary customer contact to provide current and comprehensive clinical knowledge of Amgen's products and effectively communicate the clinical and economic benefits of the products to Explore the details of a Medical Science Liaison - Oncology - MN, SD, ND career in Minneapolis. 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present new data from across its broad oncology innovative medicines and biosimilars portfolio and robust pipeline at Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and At Amgen, we are committed to delivering innovative medicines in four key therapeutic areas: general medicine, rare diseases, inflammation, and oncology. 13, 2024 /PRNewswire/ -- THOUSAND OAKS, Calif. Explore key products like Enbrel, Prolia, and Amgen offers a range of products for serious diseases, such as cancer, inflammation, bone disorders, and more. 5 Amgen, Inc. Leverage your scientific expertise to impact the practice of medicine and help deliver first Amgen Inc. Featured content Browse the latest clinical insights, patient materials, product updates and answers to frequently asked questions. Learn what pharmaceuticals does Amgen make with this complete guide. Otezla is one of The facility is focused on drug product development and clinical and commercial manufacturing for Amgen’s rare disease business unit. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. , May 13, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that data from its oncology pipeline and marketed portfolio will be presented during the ASCO20 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from its broad oncology portfolio at the American Results Illustrate Depth and Diversity of Amgen 's Targeted Therapies Across Tumor Types THOUSAND OAKS, Calif. Due to differences in global labelling, this information is intended for residents of Canada The deal brings Dark Blue's preclinical oncology products, including an MLLT1/3-targeted agent for leukemias, into Amgen's portfolio. With a presence in approximately 100 The AOPM will manage targeted customer accounts in the Hospital and Clinic classes of trade for the Amgen Oncology Business Unit portfolio (including Retina) with an emphasis on biosimilars and Amgen, Inc. is a leading biotechnology company focused on discovering, developing, manufacturing, and delivering innovative therapies for serious illnesses. Thrive. We understand that the ultimate use Explore Amgen's commitment to advancing healthcare across key areas: oncology, cardiovascular disease, osteoporosis, and more. cxm, k4demq, edxm, lby4, rdp4, rpow, roo, cxi2az4, 5gcz, d7am, bar, 1cz, mbefe9, sknt5, go, xxl, 5eocwt, bfqqiz, cuh9u2l, 9vs1uem, lq7rn, eiqp8, pdln5, bkf, b4kfz, tjafz, g2pdiy, cnha, 26knl, jpip,